We are live on ! Find out more
FM

Frazier Management Portfolio holdings

AUM $1.12M
1-Year Est. Return 151.58%
This Fund
S&P 500
This Quarter Est. Return
+4.68%
1 Year Est. Return
+151.58%
3 Year Est. Return
+408.4%
5 Year Est. Return
+1,802.6%
10 Year Est. Return
–
AUM
$882M
AUM Growth
+$286M
Cap. Flow
+$377M
Cap. Flow %
42.79%
Top 10 Hldgs %
91.23%
Holding
26
New
6
Increased
1
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
ARQT icon
Arcutis Biotherapeutics
ARQT
+$283M
2
PASG icon
Passage Bio
PASG
+$78.3M
3
ADVM
Adverum Biotechnologies
ADVM
+$11.8M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$9.3M
5
TRIL
Trillium Therapeutics Inc.
TRIL
+$9.24M

Top Sells

Rank Stock Value
1
COLL icon
Collegium Pharmaceutical
COLL
+$19.5M
2
ETTX
Entasis Therapeutics Holdings Inc.
ETTX
+$1.35M
3
KZR
Kezar Life Sciences
KZR
+$363K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARQT icon
1
Arcutis Biotherapeutics
ARQT
$3.13B
$314M 35.62%
+10,542,790
New +$283M
PHAT icon
2
Phathom Pharmaceuticals
PHAT
$723M
$188M 21.33%
7,284,269
– –
PASG icon
3
Passage Bio
PASG
$13.9M
$78.9M 8.95%
+250,461
New +$78.3M
IOVA icon
4
Iovance Biotherapeutics
IOVA
$3.74B
$52.4M 5.94%
1,750,665
– –
MIRM icon
5
Mirum Pharmaceuticals
MIRM
$6.08B
$49.9M 5.66%
3,566,912
– –
KRYS icon
6
Krystal Biotech
KRYS
$10.6B
$38.7M 4.39%
895,000
– –
ANAB icon
7
AnaptysBio
ANAB
$1.7B
$32.7M 3.71%
2,316,447
– –
TBIO
8
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$21.8M 2.47%
2,182,789
– –
COLL icon
9
Collegium Pharmaceutical
COLL
$820M
$15.4M 1.75%
943,666
-943,666
-50% -$19.5M
ADVM
10
DELISTED
Adverum Biotechnologies
ADVM
$12.5M 1.42%
127,833
+100,999
+376% +$11.8M
GRTS
11
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$12M 1.36%
2,061,758
– –
SNDX icon
12
Syndax Pharmaceuticals
SNDX
$1.8B
$10.9M 1.23%
+990,711
New +$9.3M
TRIL
13
DELISTED
Trillium Therapeutics Inc.
TRIL
$9.55M 1.08%
+2,443,809
New +$9.24M
ALPN
14
DELISTED
Alpine Immune Sciences Inc
ALPN
$7.41M 0.84%
2,571,450
– –
TPST icon
15
Tempest Therapeutics
TPST
$17.9M
$7.37M 0.84%
7,162
– –
APTX
16
DELISTED
Aptinyx Inc. Common Stock
APTX
$6.89M 0.78%
3,190,079
– –
ITRM
17
DELISTED
Iterum Therapeutics
ITRM
$4.17M 0.47%
102,554
– –
CDTX
18
DELISTED
Cidara Therapeutics
CDTX
$3.25M 0.37%
65,613
– –
ALNA
19
DELISTED
Allena Pharmaceuticals
ALNA
$3.21M 0.36%
3,330,373
– –
RCKT icon
20
Rocket Pharmaceuticals
RCKT
$397M
$2.93M 0.33%
+210,000
New +$4.16M
ETTX
21
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
$2.77M 0.31%
1,049,953
-300,000
-22% -$1.35M
NBRV
22
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$2.45M 0.28%
17,026
– –
VTVT icon
23
vTv Therapeutics
VTVT
$130M
$2.03M 0.23%
+26,550
New +$2.55M
SRRA
24
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$1.99M 0.23%
202,803
– –
BLCM
25
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$495K 0.06%
105,144
– –
1
2

Similar funds

ACMV
August Capital Management VI Palo Alto, California $1.39M AUM
FRCMI
First Round Capital Management III Philadelphia, Pennsylvania $418K AUM
DB
DCVC Bio Palo Alto, California $313K AUM
NAM
Newfleet Asset Management Hartford, Connecticut $2.05M AUM 27.28% 1-Year Est. Return
AP
Atlas Principals Charlotte, North Carolina $2.19M AUM 56.71% 1-Year Est. Return
ID
Inspire Developers Forest Hills, New York $4.07M AUM
CI
CMT Investments Chicago, Illinois $5M AUM 15.27% 1-Year Est. Return
DIF
Discovery Investment Fund Singapore $6.98M AUM

Frazier Management's Q1 2020 Portfolio in Review

As of Q1 2020, Frazier Management held 26 positions worth $882M, up 48% from $596M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Frazier Management deployed $377M of net new capital in Q1 2020, opening 6 new positions and adding to 1 existing holding. Its largest new stake was Arcutis Biotherapeutics: 10,542,790 shares worth $314M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Collegium Pharmaceutical, an estimated $19.5M trimmed.

  • Frazier Management's largest Q1 2020 buy was Arcutis Biotherapeutics: 10,542,790 shares worth $314M.
  • Frazier Management added most to Adverum Biotechnologies in Q1 2020, an estimated $11.8M increase.
  • Frazier Management's biggest Q1 2020 reduction was Collegium Pharmaceutical, cutting an estimated $19.5M.
  • Frazier Management fully exited Kezar Life Sciences in Q1 2020, selling an estimated $363K.
  • Frazier Management's ten largest holdings make up 91% of its $882M portfolio in Q1 2020.
  • Frazier Management opened 6 new positions and closed 1 in Q1 2020.
  • Frazier Management's portfolio value rose 48% quarter-over-quarter to $882M.

Based on Frazier Management's 13F filing for Q1 2020, filed 13 May 2020.